Genetic testing showed that Erb-B2 receptor tyrosine kinase 2 (ERBB2) p.5310F mutation rate was 17.7%, Tumor mutational burden-high (TMB-H) was 2.87, Microsatellite instability-high (MSI-H) was 10.68%, TPS was <1%, and CPS was <1. Here, ERBB2 is linked to neoplasm.